Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450-2C9

Biochemical Pharmacology

Volumn 52, Issue 8, 1996, Pages 1305-1309

  Tracy, Timothy S ^a   Marra, Christina ^e   Wrighton, Steven A ^b   Gonzalez, Frank J ^c   Korzekwa, Kenneth R ^d  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NONE

Author keywords

cDNA expression; cytochrome P450; flurbiprofen; human liver microsomes; vaccinia virus

Indexed keywords

4' HYDROXYFLURBIPROFEN; COMPLEMENTARY DNA; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENZYME INHIBITOR; FLURBIPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL;

EID: 0030601837     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00501-1     Document Type: Article

References (19)

1. 1. Kantor TG, Physiology and treatment of pain and inflammation: Analgesic effects of flurbiprofen. Am J Med 80 (Suppl 3A):3-9, 1986.
2. 2. Risdall PC, Adams SS, Crampton EL, and Marchant B, The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica 8: 691-704, 1978.
3. 3. Knadler MP and Hall SD, High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. J Chromatogr Biomed Appl 494: 173-182, 1989.
4. 4. Szpunar GJ, Albert KS, Bole GG, Dreyfus JN, Lockwood GF and Wagner JG, Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. Biopharm Drug Dispos 8: 273-283, 1987.
5. 5. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ and Korzekwa KR, Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49: 1269-1275, 1995.
6. 6. Veronese MS, Mackenzie PI, Doecke CJ, McManus ME, Miners JO and Birkett DJ, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175: 1112-1118, 1991.
7. 7. Zhao J, Leemann T and Dayer P, In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 51: 575-581, 1992.
8. 8. Guengerich FP, Microsomal enzymes involved in toxicology - Analysis and separation. Principles and Methods of Toxicology, pp. 609-634, Raven Press, New York, 1984.
9. 9. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
10. 10. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
11. 11. Cleland WW, Statistical analysis of enzyme kinetic data. Methods Enzymol 63: 103-138, 1979.
12. 12. Goldstein JA and de Morais SMF, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
13. 13. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252: 442-447, 1990.
14. 14. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
15. 15. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 3: 566-573, 1990.
16. 16. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T and Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5: 143-150, 1995.
17. 17. Yamazaki H, Guo Z, and Guengerich FP, Selectivity of cytochrome P4502E1 in chlorzoxazone hydroxylation. Drug Metab Dispos 23: 438-440, 1995.
18. 18. Jamali F, Berry BW, Tehrani MR, and Russell AS, Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 77: 666-669, 1988.
19. 19. Knadler MP, Brater DC, and Hall SD, Stereoselective disposition of flurbiprofen in normal volunteers. Br J Clin Pharmacol 33: 369-375, 1992.